Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL

Leukemia

Volumn 23, Issue 2, 2009, Pages 400-402

  Mussolin, L ^a   Bonvini, P ^b   Ait Tahar, K ^c   Pillon, M ^a   Tridello, G ^a   Buffardi, S ^d   Lombardi, A ^e   Pulford, K ^c   Rosolen, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d Unit di Emato oncologia Pediatrica   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; NUCLEOPHOSMIN;

ADOLESCENT; ANIMAL CELL; ANTIBODY TITER; CANCER REGRESSION; CANCER RELAPSE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; INFANT; LARGE CELL LYMPHOMA; LETTER; MALE; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

EID: 60149090318     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.184     Document Type: Letter

References (8)

1. Falini B. Anaplastic large-cell lymphoma: Pathological, molecular and clinical features. Br J Haematol 2001; 114: 741-760.
2. Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000; 96: 1605-1607.
3. Mussolin L, Pillon M, d'Amore SG, Santoro N, Lombardi A, Fagioli F et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large-cell lymphoma. Leukemia 2005; 19 1643-1647.
4. Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110: 670-677.
5. 2 in 3 hours infusion without IT: Results of the ALCL99-R1 randomised trial[abstract]. Blood 2006; 108: 122a.
6. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion transcripts for residual disease detection in leukaemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
7. Ait-Tahar K, Bernardo MCN, Pulford K. CD4 T-Helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007; 67: 1898-1901.
8. Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola N et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large-cell lymphomas. Haematologica 2006; 91: 48-55.